Market Currents
While the good news for investors of Amarin (AMRN +1.1%) is that development on its experimental...
-
Friday, March 9, 2012, 11:01 AM ETWhile the good news for investors of Amarin (AMRN +1.1%) is that development on its experimental heart drug derived from fish oil is churning right along, the bad news is that the USPTO can't keep up with the pace to help the company keep generic versions at bay. Leerink Swann predicts the patent office will eventually grant approval after a lengthy appeals process, as it maintains an Outperformance rating and $25 price target on the biotech firm.
Other date
Latest Articles
